Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Fulgent Genetics, Inc.NASDAQ: FLGT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $21.49M fell 24.2% year over year, behind the +9.3% change in trailing-twelve-month gross profit. Sequentially, it fell 34.0% from the prior quarter. Over 3 fiscal years it compounded at -29.1% a year.
Context
- Gross profit amounted to 40.6% of revenue in FY2025, up 2.7 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.2% toward the trailing-twelve-month pace of +9.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 130.88M USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- -35.9%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 130.88M | +22.1% |
| FY2024 | 2024-12-31 | 107.22M | +2.6% |
| FY2023 | 2023-12-31 | 104.46M | -71.5% |
| FY2022 | 2022-12-31 | 366.9M | -52.8% |
| FY2021 | 2021-12-31 | 777.05M | — |
Gross Profit vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 gross profit of $124.02M is the 7th highest of the 8 companies compared; the peer median is $328.9M.
- Its year-over-year change of +9.3% is the 5th highest of 8, against a peer median of +27.3%.
- Gross profit amounts to 38.7% of revenue for FLGT, versus a peer median of 65.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.77B | +43.1% | +60.2% | 65.3% | |
| LTM Sep 2026 | $833.7M | +44.9% | +29.2% | 65.2% | |
| LTM Mar 2026 | $580M | -0.3% | +6.6% | 70.0% | |
| LTM Jun 2026 | $328.9M | +8.7% | +14.6% | 42.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $309.9M | +27.3% | — | 68.2% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $283.22M | +122.4% | — | 71.3% |
| LTM Mar 2026 | $124.02M | +9.3% | -29.1% | 38.7% | |
| LTM Mar 2026 | $8.85M | -69.0% | — | 13.7% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $328.9M | +27.3% | +21.9% | 65.3% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.